Sun Pharma Takes a Risk on Skin Care Products


India’s Sun Pharmaceuticals has launched new products to boost U.S. skin care product sales and offset competition in the U.S. dermatology business.

Sun Pharma entered the roughly $5 billion U.S. dermatology space in 2010. With the new dermatology drug, tildrakizumab, the company hopes that the results of the late-stage trials will be published soon.

Controlling a stake in Israel’s Taro Pharmaceutical Industries Ltd. Sun Pharma, the world’s fifth-largest maker of generic drugs, has been has since confronted smaller players entering the dermatology field, including Lupin and Glenmark Pharmaceuticals.

More in News